Can Testosterone Replacement Therapy Lower the Risk of A Recurrence?

In a surprising study, researchers at the University of California, Irvine, led by Professor Thomas Ahlering found that in a sample of carefully selected men who had low-risk prostate cancer and who had surgery, testosterone replacement therapy significantly lowered their risk for having a prostate cancer recurrence! 

Announcing the ProVent Trial for Men on Active Surveillance

The ProVent Trial is a phase 3 trial for men on active surveillance. The trial is designed to evaluate the efficacy of Provenge for men who are still at one of the earliest stages of the disease, active surveillance. The trial’s goal is to assess the ability of Provenge to reduce the risk of disease progression in men on Active Surveillance.

Neuroticism Has A Negative Influence on Prostate Cancer Quality of Life Outcomes

In a presentation at the European Association of Urology Congress in Barcelona, Spain there was a report that showed that prostate cancer patients who had high levels of neuroticism (a broad personality trait in which a person experiences the world as distressing, threatening, and unsafe place) had significantly more adverse events following surgery, including sexual dysfunction and urinary incontinence.  The data was created from a survey of almost 1,000 men

Laser-Targeted Removal of Prostate Tumors Works as Well as the Complete Removal of the Prostate

One question we often hear at Cancer ABCs is about the efficacy of laser targeted removal of cancerous tissue from the prostate gland as opposed to removing the entire gland.  Recently described research from Dr. Eric Walser who is at The University of Texas Medical Branch at Galveston has shown that selectively destroying cancerous prostate tissue inside of the prostate gland can be as effective as the removal of the entire prostate gland.  

Black Men with Prostate Cancer Do Better with Radiation Than White Men

Recently released and unexpected findings have been announced, contrary to previous understandings, black men who received primary radiation therapy to treat their prostate cancer had lower rates of biochemical cancer recurrence than white men.  They also had a lower rate of developing distant metastasis.  These findings are from data coming from the randomized RTOG trials and were reported at the American Society of Radiation Oncology by Daniel Spratt, MD, of the University of Michigan in Ann Arbor.  

Making this finding even more interesting is the finding that Black men do better when they receive Provenge than white men      

Both of these findings point out that there are likely differences in the underlying prostate cancer disease between Black and White men.  However, this conclusion does not negate the fact that Black men have less access to treatment than White men, a fact that needs to be corrected, especially given the circumstances indicated in these two conclusions that Black men do well when given treatment.      

By Joel T. Nowak

Robotic v Open Prostate Cancer Surgery

A recent study, published in the Lancet Oncology compared robotic to open prostate cancer surgery (prostatectomy). The study found that over a two-year period both forms of surgery produced equivalent results for preserving erectile function and urinary continence.   However, there were some differences.

Cancer Insurance & Family Leave News

There are a number of items of news about state expansion of Medicaid, Family Leave and some attempts by certain states to screw their citizens who have cancer or chronic illnesses go around the federal medical insurance laws by

Hypofractionation and Hydrogel Spacer – Two New Important Changes in the Delivery of Primary Radiation Therapy for Prostate Cancer 

How radiation is delivered as a primary treatment for prostate cancer therapy has been changing, mostly since 2017.  The change involves two different items, one the method of delivery of the radiation and the increasing use of a newly developed “safety” product that lowers the adverse side effects of the radiation treatment.